Document is current
Any future updates will be listed below
-
Authors
Jhund, Pardeep S. https://orcid.org/0000-0003-4306-5317
Kondo, Toru https://orcid.org/0000-0001-6853-7574
Butt, Jawad H. https://orcid.org/0000-0002-7380-4144
Docherty, Kieran F.
Claggett, Brian L.
Desai, Akshay S.
Vaduganathan, Muthiah
Gasparyan, Samvel B. https://orcid.org/0000-0002-4797-2208
Bengtsson, Olof https://orcid.org/0000-0003-1315-8176
Lindholm, Daniel https://orcid.org/0000-0003-3526-0614
Petersson, Magnus
Langkilde, Anna Maria
de Boer, Rudolf A. https://orcid.org/0000-0002-4775-9140
DeMets, David
Hernandez, Adrian F.
Inzucchi, Silvio E.
Kosiborod, Mikhail N. https://orcid.org/0000-0002-3750-9789
Køber, Lars https://orcid.org/0000-0002-6635-1466
Lam, Carolyn S. P. https://orcid.org/0000-0003-1903-0018
Martinez, Felipe A.
Sabatine, Marc S.
Shah, Sanjiv J. https://orcid.org/0000-0002-5655-8201
Solomon, Scott D.
McMurray, John J. V. https://orcid.org/0000-0002-6317-3975
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 8 July 2022
Accepted: 26 July 2022
First Online: 27 August 2022
Competing interests
: P.S.J.’s employer, the University of Glasgow, has been remunerated by AstraZeneca for working on the DAPA-HF and DELIVER trials and by Bayer and Novo Nordisk for work on clinical trials; he has received speakers and consulting fees from Novartis and Boehringer Ingelheim, and grants from AstraZeneca and Boehringer Ingelheim. T.K. received speaker fees from Abbott, Ono Pharma, Otsuka Pharma, Novartis, AstraZeneca, Bristol Myers Squibb and Abiomed. J.B. reports advisory board honoraria from Bayer. K.F.D reports receiving honoraria from AstraZeneca and a research grant to his institution from Boehringer Ingelheim. B.L.C has received consulting fees from Boehringer Ingelheim. A.S.D has received grants and personal fees from AstraZeneca during the conduct of the study; and personal fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, Corvidia, DalCor Pharma, Relypsa, Regeneron and Merck; grants and personal fees from Alnylam and Novartis; and personal fees from Amgen, outside the submitted work. M.V. has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi and Tricog Health; speaker engagements with AstraZeneca, Novartis and Roche Diagnostics and participates on clinical trial committees for studies sponsored by Galmed, Novartis, Bayer AG, Occlutech and Impulse Dynamics. S.B.G., O.B., D.L., M.P. and A.L. are employees and shareholders of AstraZeneca. R.A.deB.’s institution, the University Medical Center Groningen, has received research grants and fees (outside the submitted work) from AstraZeneca, Abbott, Boehringer Ingelheim, Cardio Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc, Novo Nordisk and Roche. He has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche (outside the submitted work). D.D. has received consulting fees from Frontier Science, Actelion, Bristol Myers Squibb, Medtronic, Boston Scientific, GlaxoSmithKline and Merck; and has received consulting fees and is the owner of DL DeMets Consulting. A.H. has received research support from American Regent, AstraZeneca, Boehringer Ingelheim, Merck, Novartis and Verily; and has served as a consultant or on the Advisory Board for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Myokardia, Merck, Novartis and Vifor. S.I. has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. M.K. has received research grant support from AstraZeneca and Boehringer Ingelheim; has served as a consultant or on an advisory board for Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion Therapeutics, Janssen, Merck (Diabetes and Cardiovascular), Novo Nordisk, Sanofi and Vifor Pharma; has received other research support from AstraZeneca; and has received an honorarium from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. L.K. has received research support from AstraZeneca; and personal fees from Novartis and Bristol Myers Squibb as a speaker. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from AstraZeneca, Bayer, Boston Scientific and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc, Us2.ai, Janssen Research & Development LLC, Medscape, Merck, Novartis, Novo Nordisk, Radcliffe Group Ltd, Roche Diagnostics, Sanofi and WebMD Global LLC; and serves as the co-founder and nonexecutive director of Us2.ai. F.M. has received personal fees from AstraZeneca. M.S. has received grants and personal fees from AstraZeneca during the conduct of the study; has received grants and personal fees from Amgen, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck and Novartis; has received personal fees from Anthos Therapeutics, Bristol Myers Squibb, CVS Caremark, DalCor, Dyrnamix, Esperion, IFM Therapeutics and Ionis; has received grants from Daiichi-Sankyo, Bayer, Pfizer, Poxel, Eisai, GlaxoSmithKline, Quark Pharmaceuticals and Takeda outside the submitted work; and is a member of the TIMI Study Group, which has also received institutional research grant support through Brigham and Women’s Hospital from Abbott, Aralez, Roche and Zora Biosciences. S.S. has received either personal or institutional research support for DELIVER from AstraZeneca. S.D.S. has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Blood, and Lung Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos and US2.AI; and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellPro-Thera, Moderna, American Regent and Sarepta. J.J.V.M. has received payments through Glasgow University for work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, DalCor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer and Theracos; and personal lecture fees from: the Corpus, Abbott, Hikma, Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier, Director, Global Clinical Trial Partners.
